4-(4-乙基哌嗪-1-基)苯胺 | 115619-01-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(4-乙基哌嗪-1-基)苯胺
• 中文别名: 4-(4-乙基哌嗪)苯胺；4-(4-乙基-1-哌嗪基)苯胺
• 英文名称: 4-(4-ethylpiperazin-1-yl)aniline
• 英文别名: 4-(4-ethyl-piperazin-1-yl)-phenylamine；4-(4-ethyl-1-piperazinyl)aniline
• CAS: 115619-01-7
• 化学式: C₁₂H₁₉N₃
• mdl: MFCD00702246
• 分子量: 205.303
• InChiKey: KEPUOYACJXZYTQ-UHFFFAOYSA-N

物化性质

• 熔点：
  76-78°C
• 沸点：
  364.4±37.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险品运输编号：
  3259
• 海关编码：
  2933599090
• 包装等级：
  Ⅲ
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Ethylpiperazin-1-ly)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Ethylpiperazin-1-ly)aniline
CAS number: 115619-01-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H19N3
Molecular weight: 205.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-乙基哌嗪-1-基)苯胺 在 N,N-二异丙基乙胺 作用下， 以 丙醇 、 乙二醇 为溶剂， 反应 4.0h， 生成 N²-(4-amino-butyl)-9-cyclopentyl-N⁶-[4-(4-ethyl-piperazin-1-yl)-phenyl]-9H-purine-2,6-diamine
  参考文献：
  名称：

  的发现Ñ 2 - （4-氨基-环己基）-9-环戊基Ñ 6 - （4-吗啉-4-基甲基-苯基） - 9H嘌呤-2,6-二胺作为有效FLT3激酶抑制剂为急性髓性带有FLT3突变的白血病

  摘要：

  FLT3酪氨酸激酶是急性髓细胞性白血病（AML）的潜在药物靶标，因为具有FLT3-ITD突变的患者对标准细胞毒剂的反应较差，并且该疾病与FLT3的致癌特性之间存在明确的联系。我们目前具有有效的FLT3抑制活性的新型2,6,9-三取代嘌呤衍生物。铅化合物7d在生化分析中显示纳摩尔活性，并选择性阻断具有FLT3-ITD突变的AML细胞系的增殖，而其他转化的和正常的人类细胞的敏感性降低了几个数量级。经过7d处理的MV4-11细胞抑制了FLT3的磷酸化及其下游信号通路，随后抑制了G1细胞的周期和凋亡。此外，单剂皮下注射了MV4-11异种移植物的小鼠在7d内持续48小时对FLT3和STAT5磷酸化产生了持续抑制作用，这与给予参考FLT3抑制剂Quizartinib后观察到的较短作用相反。

  DOI：

  10.1021/acs.jmedchem.7b01529
• 作为产物：
  描述：

  4-硝基碘苯 在 palladium 10% on activated carbon 、 氢气 、 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 90.0 ℃ 、344.75 kPa 条件下， 生成 4-(4-乙基哌嗪-1-基)苯胺
  参考文献：
  名称：

  在9-氨基位置带有碱性苯基残基的功能化奎纳克林类似物的抗-病毒活性和类药物潜力

  摘要：

  在本文中，我们报道了用4-（4-甲基哌嗪-1-基）苯基，（1-苄基哌啶-4- yl）及其结构变体。发现在不同different病毒感染的鼠细胞模型的效价和活性方面，一些有前途的类似物在抗病毒方面比奎纳克林更有利。它们还表现出对人类病毒蛋白片段的更高结合亲和力（hPrP 121–231）比奎纳克林高，并且在PAMPA-BBB分析中的渗透率在CNS渗透候选物范围内。当在过表达Pgp的细胞系上进行双向分析评估时，与奎纳克林相比，一种类似物对Pgp外排活性的敏感性较低。两者合计，结果表明连接到a啶，四氢ac啶和喹啉骨架上的取代9-氨基侧链的重要作用。该侧链的性质影响基于细胞的效能，PAMPA渗透性和对hPrP 121-231的结合亲和力。

  DOI：

  10.1016/j.ejmech.2011.04.016

文献信息

• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• [EN] PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-D]PYRIMIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2021074251A1

  公开（公告）日：2021-04-22

  The invention provides compounds of the formula (1): or a salt or tautomer thereof wherein A, R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are inhibitors of Wee1 and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers.

  这项发明提供了式（1）的化合物：或其盐或互变异构体，其中A、R1、R2、R3、R4、R5和R6如本文所定义。这些化合物是Wee1和/或PLK1激酶的抑制剂，预计在癌症治疗中有用。
• [EN] IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'IMIDAZOLYL KINASE ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016014542A1

  公开（公告）日：2016-01-28

  The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

  本公开提供了公式(I)的咪唑啉化合物及其制备方法。所提供的化合物能够结合蛋白激酶，并且可能在调节（例如，抑制）主体或细胞中的蛋白激酶活性以及/或在需要治疗的主体中治疗或预防疾病（例如，增殖性疾病、遗传性疾病、血液病、神经病、疼痛状况、精神障碍或代谢障碍）方面有用。此外，还提供了包括或涉及本文所述化合物的药物组合物、试剂盒、方法和用途。
• Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma
  作者：Bin Wu、Song Yang、Tuo Deng、Changyuan Wang、Yue Jin、Jiawen Yu、Youjun Xu、Lixue Chen、Yanxia Li、Xiaodong Ma

  DOI：10.1016/j.bioorg.2021.105330

  日期：2021.11

  A series of cyano-substituted 2,4-diarylaminopyrimidines was designed and synthesized as potent non-covalent JAK3 inhibitors. Among the derivatives synthesized, 9o (IC50 = 22.86 nM), 9 k (IC50 = 21.58 nM), and 9j (IC50 = 20.66 nM) demonstrated inhibitory potencies against JAK3 similar to the known JAK3 inhibitor tofacitinib (IC50 = 20.10 nM). Moreover, 9o displayed potent anti-proliferative activities

  设计并合成了一系列氰基取代的 2,4-二芳基氨基嘧啶作为有效的非共价 JAK3 抑制剂。在合成的衍生物中，9o (IC 50  = 22.86 nM)、9 k (IC 50  = 21.58 nM) 和9j (IC 50  = 20.66 nM) 对 JAK3 的抑制效力类似于已知的 JAK3 抑制剂托法替尼 (IC 50  = 20.10)毫）。此外，9o对 Raji 和 Ramos 细胞显示出有效的抗增殖活性，IC 50值分别为 0.9255 μM 和 1.405 μM。此外，9o在正常 HBE（人支气管上皮细胞，IC50  > 10 μM）和 L-02（人肝细胞，IC 50  = 3.104 μM）细胞。流式细胞术对作用方式的分析表明，9o在 G2/M 期有效地阻止了 Raji 细胞。综上所述，这些结果表明9o可能是作为 B 细胞淋巴瘤潜在治疗方法开发的有希望的候选者。
• PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20180072720A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  揭示了化合物的公式（I），使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与HPK1活性相关的疾病或紊乱方面是有用的，如癌症。